Table I.
Fold overexpression | ||||
---|---|---|---|---|
|
||||
Symbol | Description | P-value | Cancer vs. benign | Benign/cancer vs. castrated |
CRISP3 | Cysteine-rich secretory protein 3 | <0.001 | 5.78 | −3.08 |
FOS | FBJ murine osteosarcoma viral oncogene homologue | <0.001 | 4.76 | |
PCGEM1 | Prostate-specific transcript 1 (non-protein coding) | <0.001 | 4.42 | |
MYBPC1 | Myosin binding protein C, slow type | <0.001 | 4.30 | |
PCA3 | Prostate cancer antigen 3 (non-protein coding) | <0.001 | 4.18 | 3.74 |
OR51E2 | Olfactory receptor, family 51, subfamily E, member 2 | <0.001 | 4.01 | 3.29 |
ANPEP | Alanyl (membrane) aminopeptidase | <0.001 | 3.84 | |
DPP4 | Dipeptidyl-peptidase 4 | 0.005 | 3.79 | |
GCNT2 | Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group) | 0.001 | 3.73 | |
HOXC6 | Homeobox C6 | 0.003 | 3.69 | −2.62 |
AGR3 | Anterior gradient homologue 3 (Xenopus laevis) | 0.003 | 3.63 | 3.00 |
RGS1 | Regulator of G-protein signalling 1 | 0.002 | 3.55 | |
NR4A2 | Nuclear receptor subfamily 4, group A, member 2 | 0.002 | 3.50 | |
DUSP1 | Dual specificity phosphatase 1 | 0.011 | 3.48 | |
AMACR | α-methylacyl-CoA racemase | 0.008 | 3.40 | 3.00 |
LOC728606 | Hypothetical LOC728606 | 0.015 | 3.36 | |
DLX1 | Distal-less homeobox 1 | 0.011 | 3.30 | |
VEGFA | Vascular endothelial growth factor A | 0.004 | 3.30 | |
MSMB | Microseminoprotein, β- | 0.006 | 3.21 | |
TDO2 | Tryptophan 2,3-dioxygenase | 0.025 | 3.19 | |
NCAPD3 | Non-SMC condensin II complex, subunit D3 | 0.008 | 3.14 | |
EGR1 | Early growth response 1 | 0.027 | 3.14 | |
CD38 | CD38 molecule | 0.008 | 3.13 | |
C15orf48 | Chromosome 15 open reading frame 48 | 0.022 | 3.11 | |
RASD1 | RAS, dexamethasone-induced 1 | 0.030 | 3.09 | |
AGR2 | Anterior gradient homologue 2 (Xenopus laevis) | 0.023 | 3.07 | |
SORD | Sorbitol dehydrogenase | 0.012 | 3.02 | |
C12orf56 | Chromosome 12 open reading frame 56 | 0.037 | 3.01 | |
SFTPA2 | Surfactant protein A2 | 0.037 | 2.99 | |
ST6GALNAC1 | ST6 (α-N-acetyl-neuraminyl-2,3-β-galactosyl-1,3)-N-acetylgalactosaminide α-2,6-sialyltransferase 1 | 0.038 | 2.98 | |
ACADL | Acyl-CoA dehydrogenase, long chain | 0.013 | 2.98 | |
EGR3 | Early growth response 3 | 0.044 | 2.94 | |
ERG | V-ets erythroblastosis virus E26 oncogene homologue (avian) | 0.045 | 2.90 | |
FOSB | FBJ murine osteosarcoma viral oncogene homologue B | 0.016 | 2.90 | |
SCD | Stearoyl-CoA desaturase (δ-9-desaturase) | 0.024 | 2.80 | |
GNMT | Glycine N-methyltransferase | 0.028 | 2.76 | |
CCK | Cholecystokinin | 0.028 | 2.75 | |
PEBP4 | Phosphatidylethanolamine-binding protein 4 | 0.031 | 2.72 | |
ATF3 | Activating transcription factor 3 | 0.031 | 2.71 | |
HLA-DQA1 | Major histocompatibility complex, class II, DQ α 1 | 0.032 | 2.70 | |
SELE | Selectin E | 0.035 | 2.66 | |
PENK | Proenkephalin | 0.043 | 2.61 | |
CD177 | CD177 molecule | 0.048 | 2.58 | |
MALAT1 | Metastasis-associated lung adenocarcinoma transcript 1 (non-protein coding) | 0.032 | −2.69 | |
ASPN | Asporin | 0.029 | −2.74 | |
PSPH | Phosphoserine phosphatase | 0.027 | −2.77 | |
SLC14A1 | Solute carrier family 14 (urea transporter), member 1 (Kidd blood group) | 0.048 | −2.88 | −3.05 |
HBB | Haemoglobin, β | 0.016 | −2.89 | |
SCGB1A1 | Secretoglobin, family 1A, member 1(uteroglobin) | 0.045 | −2.91 | |
KRT14 | Keratin 14 | 0.032 | −2.99 | |
NEFH | Neurofilament, heavy polypeptide | 0.022 | −3.10 | |
TMEM45B | Transmembrane protein 45B | 0.007 | −3.16 | |
GPM6A | Glycoprotein M6A | 0.027 | −3.17 | |
RLN1 | Relaxin 1 | 0.016 | −3.21 | |
GREM1 | Gremlin 1 | 0.004 | −3.29 | |
MME | Membrane metallo-endopeptidase | 0.004 | −3.57 | |
CXCL13 | Chemokine (C-X-C motif) ligand 13 | 0.003 | −3.67 | |
CYP3A5 | Cytochrome P450, family 3, subfamily A, polypeptide 5 | 0.001 | −3.92 | |
WIF1 | WNT inhibitory factor 1 | <0.001 | −4.14 |
Gene symbols and gene descriptions are presented.
P-values for differential expression were produced using Chipster software. Only genes with P-values <0.05 are presented. Negative values in the fold overexpression column indicate that the gene was underexpressed in cancer compared with benign samples or underexpressed in benign or cancer samples compared with castrated samples.